Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 38Breast 20Tumor-Agnostic 3Other solid neoplasm 3Head & Neck 3Gynecologic 1

Conditions

Nasopharyngeal Carcinoma 3

Interventions

Cisplatin 47pembrolizumab 36Magnetic Resonance Spectroscopy 35Specimen Handling 28Radiotherapy, Intensity-Modulated 21Carboplatin 19Platinum 16Nivolumab 16Cetuximab 161,2-diaminocyclohexaneplatinum II citrate 16Radiotherapy 15Biopsy 13Paclitaxel 11Gemcitabine 10Radiation 9Docetaxel 8Taxes 7Fluorouracil 7cemiplimab 6Surveys and Questionnaires 6toripalimab 5atezolizumab 5X-Rays 5Watchful Waiting 5Ipilimumab 5Immunoglobulin G 5Disulfides 5Bevacizumab 5dostarlimab 4dabrafenib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Capecitabine × Head & Neck × 30 days × Clear all
NCT07590024 2026-05-20

RAIRI-NPC

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 3 Recruiting
651 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT06277050 2026-05-15

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

Jiangxi Provincial Cancer Hospital

Phase 3 Recruiting
264 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT05201859 2026-05-07

Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 2 Active not recruiting
150 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡